骨肉瘤患者血清外泌体中miR-193a和miR-21-5p表达水平及其临床意义

doi:10.3969/j.issn.1004-616x.2023.03.007

Abstract

Abstract: OBJECTIVE：To observe expression levels of serum exocrine miR-193a and miR-21-5p in patients with osteosarcoma，and to explore their diagnostic and prognostic values. METHODS：A total of 112 osteosarcoma patients who visited our hospital from January 2016 to December 2021 were collected as the study subjects，and 100 healthy people as the controls. From all individuals，5mL peripheral blood were collected from each，and serum samples were isolated for exosomes collection. Expression levels of miR-193a and miR-21-5p were detected by real-time quantitative PCR (qPCR). ROC curves were used to evaluate diagnostic values of miR-193a and miR-21-5p for osteosarcoma，and to analyze their correlation with clinical features and prognosis. RESULTS：Expression levels of miR-193a and miR-21-5p from patients were significantly higher than those from controls (P<0.05). The osteosarcoma diagnosis AUC of miR-193a and miR-21-5p were 0.811 and 0.880，respectively. Their sensitivities were 89.2% and 90.2%，and the specificities were 75.0% and 84.0%，respectively. The osteosarcoma diagnosis AUC of the combined method was 0.901，which was higher than that of the single index. The sensitivity and specificity were 92.1% and 86.5%，respectively. Osteosarcoma patients with high expression levels of miR-193a and miR-21-5p were often associated with advanced TNM stages，risk of distant organ metastasis and worse prognosis (P<0.05). CONCLUSION：The expression levels of miR-193a and miR-21-5p in the serum exosomes from osteosarcoma patients were significantly increased. The increase was associated with advanced TNM stages，higher risk of distant organ metastasis and worse prognosis. Thus，serum secretions of miR-193a and miR-21-5p can be considered as biomarkers for diagnosis and prognosis of osteosarcoma.

Key words: exosome, miR-193a, miR-21-5p, osteosarcoma, diagnosis, prognosis

CLC Number:

R738.1

WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.

References

[1] BOTTER S M, NERI D, FUCHS B. Recent advances in osteosarcoma[J]. Curr Opin Pharmacol, 2014, 16:15-23.
[2] GILL J, GORLICK R. Advancing therapy for osteosarcoma[J]. Nat Rev Clin Oncol, 2021, 18(10):609-624.
[3] NAM G H, CHOI Y, KIM G B, et al. Emerging prospects of exosomes for cancer treatment:from conventional therapy to immunotherapy[J]. Adv Mater, 2020, 32(51):e2002440.
[4] MITCHELL P S, PARKIN R K, KROH E M, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30):10513-10518.
[5] YU X J, ODENTHAL M, FRIES J W U. Exosomes as miRNA carriers:formation-function-future[J]. Int J Mol Sci, 2016, 17(12):2028.
[6] WU Z Y, ZHOU Z, ZHANG W G, et al. miR-21-5p inhibition attenuates Warburg effect and stemness maintenance in osteosarcoma cells via inactivation of Wnt/β-catenin signaling[J]. Acta Biochim Pol, 2021, 68(4):725-732.
[7] QI J, ZHANG R H, WANG Y P. Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1[J]. J Cell Mol Med, 2021, 25(23):11016-11030.
[8] CHEN R Q, NING Y C, ZENG G R, et al. The miR-193a-5p/NCX2/AKT axis promotes invasion and metastasis of osteosarcoma[J]. J Cancer, 2021, 12(19):5903-5913.
[9] 向黎娜, 张卫国. 骨肉瘤患者组织和血清中环状RNA hsa_circ_0005721表达水平及临床意义[J]. 临床与病理杂志, 2020, 40(5):1136-1143.
[10] WANG X X, WU L H, AI L P, et al. Construction of an HCC recurrence model basedon the investigation of immune-relatedlncRNAs and related mechanisms[J]. Mol Ther Nucleic Acids, 2021, 26:1387-1400.
[11] IACONA J R, LUTZ C S. miR-146a-5p:expression, regulation, and functions in cancer[J]. Wiley Interdiscip Rev RNA, 2019, 10(4):e1533.
[12] ZHU M Z, WANG X C, GU Y T, et al. MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway[J]. Arch Biochem Biophys, 2019, 661:22-30.
[13] LI Q, LI B W, LI Q, et al. Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition[J]. Cell Death Dis, 2018, 9(9):854.
[14] REN X F, SHEN Y Q, ZHENG S Y, et al. miR-21 predicts poor prognosis in patients with osteosarcoma[J]. Br J Biomed Sci, 2016, 73(4):158-162.
[15] NAKKA M, ALLEN-RHOADES W, LI Y T, et al. Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma[J]. Oncotarget, 2017, 8(57):96738-96752.
[16] LIN C H, TSAI C H, YEH C T, et al. miR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma[J]. Oncotarget, 2016, 7(26):39680-39693.
[17] SUN H, YAN J H, TIAN G Y, et al. LINC01224 accelerates malignant transformation via miR-193a-5p/CDK8 axis in gastric cancer[J]. Cancer Med, 2021, 10(4):1377-1393.
[18] YONG F L, LAW C W, WANG C W. Potentiality of a triple microRNA classifier:miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer[J]. BMC Cancer, 2013, 13:280.
[19] DENG H, LV L, LI Y, et al. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway[J]. Mol Cancer, 2014, 13:234.
[20] JACQUES C, CALLEJA L R, BAUD'HUIN M, et al. miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors[J]. Oncotarget, 2016, 7(34):54503-54514.
[21] RAIMONDI L, LUCA A D, GALLO A, et al. Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs[J]. Carcinogenesis, 2020, 41(5):666-677.

Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[2]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.
[3]	TAN Jianhua, LAI Yaozhen, TANG Lihua, ZHOU Li. Efficacy and prognostic values of two treatments for advanced epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 131-138.
[4]	HU Xueyi, SHEN Feng, WU Lun, SU Caiwu, WEI Jian. SPON2 expression in papillary thyroid carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 9-14.
[5]	XU Hao, HU Bichuan, ZOU Wei, DUAN Yabin. Identification of prognostic factors among patients with stage Ⅲ gastric cancer undergoing radical resection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 30-36.
[6]	LIU Xia, GAO Zibo, DING Lihua, WU Yongjun. Screening of plasma exosome microRNAs in patients with lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 407-412.
[7]	LI Yan, DONG Jingru, WEI Yuanyuan, ZHANG Jinyan. Expression and clinical significance of AURKA in cervical cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 421-428.
[8]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[9]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[10]	ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.
[11]	ZHANG Yuling, LIU Ditian, CHEN Chunfa. Impact of CD68 macrophage infiltration on prognosis in primary small cell esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 279-283.
[12]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[13]	LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.
[14]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[15]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.